Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Subcutaneous (SC) injection is currently the most common route of self-administering biopharmaceuticals such as proteins and peptides. While pharmaceutical scientists have acquired great skill in identifying formulations for these proteins and peptides with multi-year shelf life stability, the SC injection of these formulations can result in inconsistent or particularly low bioavailability outcomes. We hypothesise that upon injection, the chemical, physical and physiological properties of the subcutaneous tissue may play a crucial role in determining the therapeutic outcomes of SC injected biopharmaceuticals. We contend that physical and chemical stresses placed upon the injected protein or peptide as it transitions from the non-physiological environment of its formulation to the homeostatic conditions of the SC tissue can affect its fate following injection, and that by taking this environment into account when formulating, more precisely controlled release of SC injected biopharmaceuticals could be achieved. In this mini-review we describe how events that occur to an injected protein or peptide during this post-injection transition period could affect the diffusion of bioactive material to blood capillaries and lymphatic vessels. With this in mind, we have reviewed the chemical, physical and physiological attributes of the SC tissue and collated studies on how these properties are known to affect protein stability and diffusional properties. Finally, examples where the understanding of the properties of the SC tissue when formulating for SC injected biopharmaceuticals has improved the predictability of drug delivery via the SC route are discussed, with the need for novel tools for rational and informed formulation development highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyaluronan: its nature, distribution, functions and turnover.
Fraser, J. R. E., Laurent, T. C., & Laurent, U. B. G. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.00170.x · Cited by 2,031
Hyaluronan-binding Proteins: Tying Up the Giant
Day, A. J., & Prestwich, G. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100036200 · Cited by 567
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398 · cited 1×
“The relationship between the pharmacokinetic (PK) and pharmacodynamic (PD) properties of intravenously administered mAb formulations and protein charge have also been investigated, and it was concluded that after extravasation, electrostatic ECM–protein interactions played a part in determining PK/ PD properties [56,5…”
BackgroundMechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377 · cited 1×
“Formulation testing is currently performed in animals, but these are limited in their predictive capabilities of biopharmaceutical drug stability and extent of absorption in man upon injection, possibly due to anatomical and physiological differences between species [94].”
BackgroundFrost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · cited 1×
“This enzyme has been added to biopharmaceutical formulations to enable increasing injection volumes and to enhance biopharmaceutical transport through interstitial spaces as a result of the breakage of the diffusional barrier posed by HA, consequentially improving their bioavailability [89,90].”
BackgroundComposition of interstitial fluid
Fogh-Andersen, N., Altura, B. M., Altura, B. T., & Siggaard-Andersen, O. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1522 · Cited by 309
A recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
Bumbaca, D., Boswell, C. A., Fielder, P. J., & Khawli, L. A. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9369-y · Cited by 119
Morello, C. (2011) · International Journal of General Medicine · doi:10.2147/ijgm.s26889 · Cited by 71
Cited by
Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns
Richter, W. F., & Jacobsen, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059238 · Cited by 235
Tibbitts, J., Canter, D., Graff, R., Smith, A., & Khawli, L. A. (2016) · mAbs · doi:10.1080/19420862.2015.1115937 · Cited by 209
Role of Buffers in Protein Formulations
Zbacnik, T. J., Holcomb, R. E., Katayama, D. S., Murphy, B. M., Payne, R. W., Coccaro, R. C., Evans, G. J., Matsuura, J. E., Henry, C. S., & Manning, M. C. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.11.014 · Cited by 195
Doughty, D. V., Clawson, C. Z., Lambert, W., & Subramony, J. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.04.009 · Cited by 74
In vitro models for immunogenicity prediction of therapeutic proteins
Groell, F., Jordan, O., & Borchard, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.06.008 · Cited by 53
Metadata
- Authors
- Kinnunen, H. M., & Mrsny, R. J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 182
- Pages
- 22-32
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2047699078
- Cited by
- 163
- References
- 9
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.